Nykode Therapeutics Asa · OSL:NYKD
Nykode Therapeutics Asa — FY2021 Earnings Presentation
32 slides from Nykode Therapeutics Asa's earnings presentation, Apr 1, 2022
Slide 1: FY 2021 Presentation
FY 2021 Presentation April 1, 2022
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: Today's presenters from Nykode management
Today’s presenters from Nykode management International management team with solid drug development experience MICHAEL ENGSIG AGNETE B. FREDRIKSEN HARALD GURVIN CEO Chief Innovation & Strategy Officer CFO M.Sc. Biochemistry and G.D.Bus.Admin. M.Sc. in Molecular Biology and Ph.D. in M.Sc. in Shipping
Slide 4: 2021 was another year of significant progress
On the agenda “2021 was another year of significant progress” 01 Partnerships 02 Pipeline and Technology 03 Organisation 04 Financial Nykode Therapeutics | Webcast | Non-confidential 4
Slide 5: Overview
Overview Proprietary Vaccibody™ immunotherapy platform uniquely targets Antigen Presenting Cells (APCs) for a potent, broad and lasting immune response Pipeline of oncology and infectious disease vaccines includes partnered programs and wholly-owned clinical candidates Potentially more than $1
Slide 6: Partnerships
Partnerships 6
Slide 7: Two new transformative collaboration and license agreements
Two new transformative collaboration and license agreements with top-tier US biopharma partners. Genentech partnership progressing well. Partner Collaboration • Worldwide, exclusive rights to Adaptive’s clinically validated SARS-CoV-2 T cell epitopes • Novel and unique approach address current and f
Slide 8: Pipeline & Technology
Pipeline & Technology Re cy
Slide 9: Pipeline
Pipeline Discovery/ Upcoming Program Indication Phase 1 Phase 2 Phase 3 Partnerships Preclinical Milestones Nykode VB10.16 (off-the-shelf) HPV16+ cervical cancer3 3 1H22: Interim Data Oncology Internal (off-the-shelf) Undisclosed VB10.COV2 SARS-CoV-2 4 3Q22: Interim Infectious data Disease Internal
Slide 10: VB10.16 Overview
01 VB10.16 Overview Nykode’s off the shelf vaccine targeting HPV16+ cancers Nykode Therapeutics | Webcast | Non-confidential 10
Slide 11: VB10.16 & Atezolizumab in advanced Cervical Cancer – steady progress
VB C-02: VB10.16 & Atezolizumab (Tecentriq®) in advanced Cervical Cancer – steady progress A Multi-Centre, Open-label Phase 2a Steady progress on recruitment, Trial of the Combination of VB10.16 and despite Covid-19 challenges Atezolizumab in Patients with Advanced Interim safety analysis in 2Q
Slide 12: VB10.NEO Overview
02 VB10.NEO Overview Nykode’s individualized cancer vaccine Nykode Therapeutics | Webcast | Non-confidential 12
Slide 13: VB N-02: Dose escalation study of VB10.NEO & Atezolizumab
VB N-02: Dose escalation study of VB10.NEO & Atezolizumab (Tecentriq®) Successful execution of Roche and A Phase 1B, Open-Label, Genentech collaboration on Dose-Escalation Study of the Safety individualized cancer vaccine of and Antigen-specific Immune development through multiple teams Response
Slide 14: Immune cells infiltrate the muscle specifically in areas expressing CCL3L1 Vaccibody protein
Immune cells infiltrate the muscle specifically in areas expressing the CCL3L1 Vaccibody protein, in mice • Vaccibody protein expression can be detected directly in muscle cells by microscopy after i.m. DNA delivery. • Dendritic cells, B cells and monocytes are attracted specifically to the CCL3L1 V
Slide 15: Activated CD4 and CD8 T cells in muscle dependent on CCL3L1 targeting
Activated CD4 and CD8 T cells in muscle is dependent on CCL3L1 targeting, in mice Nykode Therapeutics | Webcast | Non-confidential Siri Tahtinen S, Mark McCarron, et al (Genentech, Inc) Note: poly IC is a positive control given at day 6
Slide 16: Infectious disease programs
03 Infectious disease programs Nykode Therapeutics | Webcast | Non-confidential 16
Slide 17: Created the first clinical infectious disease candidate and vaccinated first patient
Created the first clinical infectious disease candidate and vaccinated first patient BETA – (PSEUDOVIRUS NEUTRALIZATION ASSAY) Designed the first clinical candidate for infectious diseases Included differentiated antigen, from beta RBD Demonstrated rapid onset of strong neutralizing antibody r
Slide 18: First T cell focused infectious disease vaccine in collaboration with Adaptive
Created the first T cell focused infectious disease vaccine (Covid-19) in collaboration with Adaptive Biotechnologies • Nykode’s CCL3L1-targeting unit has shown to induce a differentiated T cell response, in particular broader CD8 T cell response 8 • T cells have an important role in controlling inf
Slide 19: Phase 1/2 trial investigating two candidates as a diverse booster
Phase 1/2 trial investigating two candidates as a diverse booster in previously vaccinated subjects A Phase 1/2, open label, dose VB-D-01 TRIAL DESIGN escalation trial «RBD» CANDIDATE First subject with RBD candidate Candidate 1: dosed Nov. 3, 2021; first patient Healthy Cohort 1: Cohort 2: with
Slide 20: Further details on the application of Nykode's modular platform
Presented further details on the application of Nykode’s modular platform APC-specific Ag delivery and Expanded use of modularity stimulation Building additional Novel Infectious disease Cancer vaccines combinations and vaccines modules structures Vaccines against Novel therapeutics autoimmunity and
Slide 21: 2021: A year with multiple new innovations
2021: A year with multiple new innovations Breaking down the boundaries of conventional drug design Example: Cytokine empowered 2nd generation CCL3L1 CCL3L1 vaccine platform CH3 • Vaccibody molecule co-expressed with immune- 1 stimulatory proteins DNA • Both expressed from one plasmid using a multic
Slide 22: Expanding the APC-targeted modular format to explore Ag-specific immune tolerance
Initiated research to expand the use of the APC-targeted modular format as a platform to explore Ag-specific immune tolerance CANCER AND INFECTIOUS DISEASE AUTOIMMUNITY, ALLERGY ETC Stimulatory Tolerogenic DC DC Natural ligands or scFv binding diverse set of surface receptors IL-12, IFNγ, TNFα, IFNα
Slide 23: Organization
Organization 23
Slide 24: Continued strong growth across the organization
Continued strong growth across the organization Number of employees Distribution on March Gender distribution from 2020 to 2022 31, 2022 across the Nykode group Other 128 11% 125 102 CMC Female Male Total 100 16% Norway 57 (66%) 30 (34%) 87 (100%) 75 51 54% Denmark 10 (67%) 5 (33%) 15 (100%) 50 Grou
Slide 25: Strengthening the Nykode leadership team
Strengthening the Nykode leadership team Harald Gurvin, CFO Mikkel W. Pedersen, CSO Elise Ramse, CHRO • Long career in the • Head of Biologics • Extensive experience field of finance Drug Design at with HR and • CFO at Flex LNG, Servier organizational listed on both the • CSO of Symphogen, developme
Slide 26: And the Board of Directors
And the Board of Directors Martin Nicklasson, Birgitte Volck, Member of the Board and Chair of the Board and Chair of Remuneration Co-chair of R&D committee Committee Currently, serves as: Currently serves as: • Chair of Zealand Pharma A/S and on the • Senior Vice President, Head of Clinical board o
Slide 27: New flagship lab opened in Oslo Science City
New flagship lab opened in Oslo Science City Nykode Therapeutics | Webcast | Non-confidential 27
Slide 28: Financials
Financials 28
Slide 29: Strong financial foundation for achieving our vision
Strong financial foundation for achieving our vision Financially well positioned to grow and execute the Company’s strategy over the next years Strong balance sheet YE 2021 liquidity of $228 mill Milestone payment of $20 mill for initiation of Phase 1b trial in 2H 2021 received 1Q 2022 Nykod
Slide 30: Income Statement
Income Statement Revenue from contracts with customers Amounts in USD ‘000 FY 2021 FY 2020 • $30m upfront payment from Regeneron in 4Q 2021 Revenue from contracts with customers 33,963 215,000 • $4m relating to R&D activities under Genentech Other income 1,803 695 agreement in 2021 Total revenue and
Slide 31: Balance Sheet
Balance Sheet Cash and cash equivalents Amounts in USD ‘000 31/12/2021 31/12/2020 • Strong cash position of $216.2 million as per ASSETS December 31, 2021 Non-current assets Other current financial assets Property, plant and equipment 1,884 131 Right-of-use assets 7,281 277 • Liquid money market fun
Slide 32: Balance Sheet - contd.
Balance Sheet - contd. Amounts in USD ’000 31/12/2021 31/12/2020 Equity EQUITY AND LIABILITIES • Total equity of $194.1m as per December 31, 2021 Equity Share capital 333 327 • $20m equity investment from Regeneron in 4Q Share premium 81,526 60,348 2021 Other capital reserves 7,863 4,419 • Equity ra